Cytokinetics, Incorporated shares fall 1.56% intraday after reporting earnings and regulatory updates.

Cytokinetics, Incorporated declined 1.56% in intraday trading, with the company reporting earnings results for the second quarter of 2025. The company highlighted progress in regulatory reviews for Aficamten in the U.S., E.U., and China, with a late-cycle meeting with the U.S. FDA scheduled for September ahead of the December 26, 2025 PDUFA date. Additionally, the company announced that primary results from the MAPLE-HCM study will be presented in a hotline session at the European Society of Cardiology Congress 2025.